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ABSTRACT
A wide range of the epigenetic effectors that regulate chromatin modification,
gene expression, genomic stability, and DNA repair contain structurally conserved
domains called plant homeodomain (PHD) fingers. Alternations of several PHD fingercontaining proteins (PHFs) due to genomic amplification, mutations, deletions,
and translocations have been linked directly to various types of cancer. However,
little is known about the genomic landscape and the clinical significance of PHFs
in breast cancer. Hence, we performed a large-scale genomic and transcriptomic
analysis of 98 PHF genes in breast cancer using TCGA and METABRIC datasets and
correlated the recurrent alterations with clinicopathological features and survival
of patients. Different subtypes of breast cancer had different patterns of copy
number and expression for each PHF. We identified a subset of PHF genes that was
recurrently altered with high prevalence, including PYGO2 (pygopus family PHD finger
2), ZMYND8 (zinc finger, MYND-type containing 8), ASXL1 (additional sex combs
like 1) and CHD3 (chromodomain helicase DNA binding protein 3). Copy number
increase and overexpression of ZMYND8 were more prevalent in Luminal B subtypes
and were significantly associated with shorter survival of breast cancer patients.
ZMYND8 was also involved in a positive feedback circuit of the estrogen receptor
(ER) pathway, and the expression of ZMYND8 was repressed by the bromodomain
and extra terminal (BET) inhibitor in breast cancer. Our findings suggest a promising
avenue for future research—to focus on a subset of PHFs to better understand the
molecular mechanisms and to identify therapeutic targets in breast cancer.

by “reader” proteins that recognize and are recruited to
the modified histone [3, 4]. One of the largest families
of epigenetic effectors capable of “reading” posttranslationally modified or unmodified histone tails
consists of plant homeodomain (PHD) fingers. They recruit
various nuclear complexes to chromatin and stabilize them
[3, 5]. Among PHD finger-containing proteins (PHFs),
the PHD finger exists singly or in multiple copies, in
the absence of or in conjunction with other functional
modules, such as distinct histone “reading” domains,
e.g., bromo-, chromo-, and Tudor domains, or a catalytic

INTRODUCTION
Histone modifications, such as methylation and
acetylation, play critical roles in chromatin function,
transcriptional regulation, genomic stability, and DNA
repair [1, 2]. These epigenetic modifications are mediated
by sets of enzymatic complexes that have complementary
but opposing functions, namely the “writers,” which
catalyze methylation and acetylation in a site-specific
manner, and the “erasers,” which remove the modification
marks [1, 2]. Such modification marks are interpreted
www.impactjournals.com/oncotarget
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histone-associating module, such as ATPase, SET
(Suppressor of variegation, Enhancer of zeste, Trithorax),
and Jumonji C domains [4, 5]. PHFs can be broadly
divided into the following three subgroups based on
their additional functional domains and biological roles:
“Epigenetic Writers,” including histone methyltransferases
and acetyltransferases; “Epigenetic Erasers,” including
histone demethylases; and “Epigenetic Readers.” Thus,
PHFs are vital players in regulating and maintaining the
physiological functioning of epigenetic modifications in
a highly context-dependent manner. Consequently, when
PHFs malfunction, they are implicated in a broad range of
human diseases, including cancer.
Breast cancer is the most common malignant
disease in women, with more than 240,000 new cases
diagnosed and 40,000 deaths in the United States per
year. This heterogeneous disease is categorized into five
molecular subtypes: Luminal A, Luminal B, epidermal
growth factor receptor 2–enriched (HER2+), basal-like,
and normal-like breast cancers [6, 7]. The majority of
breast cancers (~70%) belong to the Luminal (A and B)
subtypes, characterized by expression of the estrogen
receptor-α (ERα). ERα is the principal biomarker for
directed hormone therapies and is the primary therapeutic
target in breast cancer [8]. Luminal B breast cancers have
lower expression of ERα and higher histologic grade, and
they are less responsive to hormone therapy and have
poorer outcomes than Luminal A [9]. Furthermore, basallike breast cancer usually occurs in young women and is
a highly aggressive subtype associated with very poor
prognosis [10]. By deeply understanding the genetic and
epigenetic alterations that are associated with the different
types of breast cancer, we can identify new druggable
subtype-specific targets for effective therapies.
Recent studies revealed that tumors, including
breast cancer, have frequent genetic alterations in histone
modifiers, including PHFs [18-20]. PHD fingers have
been shown to play a critical role in oncogenic drivers;
for example, a chromosomal translocation in the PHD
finger of PHF23 or lysine (K)-specific demethylase 5A
(KDM5A) was implicated in acute myeloid leukemia
[11, 12]. We demonstrated that KDM4C and KDM5A are
frequently amplified and overexpressed in breast cancer,
particularly in aggressive basal-like subtypes [13, 14].
The PHD fingers in histone lysine methyltransferase
WHSC1 (Wolf-Hirschhorn syndrome candidate 1)
are critical for recruiting WHSC1 to oncogenic gene
loci and driving multiple myeloma [15]. WHSC1L1,
a homolog of WHSC1, is significantly amplified and
overexpressed in a subset of breast, lung, and pancreatic
cancers [16, 17]. Furthermore, the bromodomain PHD
finger transcription factor (BPTF) is amplified and
overexpressed in melanomas, and BPTF is required for
c-MYC transcriptional activity and in vivo tumorigenesis
[18]. In contrast, a chromodomain helicase DNA binding 5
(CHD5) gene, which encodes an ATPase-dependent DNAwww.impactjournals.com/oncotarget

binding protein with two PHDs, is a tumor suppressor
in neuroblastomas. PHD-mediated histone 3 binding is
required for CHD5-mediated tumor suppression [19, 20].
In addition, the additional sex combs like 1 (ASXL1) is one
of the most frequently mutated genes in malignant myeloid
diseases, and ASXL1 mutations are strongly associated
with a poor prognosis in these myeloid disorders [21, 22].
The initiation and progression of hematological
malignancies and solid tumors have been associated
with dysregulation of several PHFs. However, little is
known about the rest of the genomic landscape and the
clinical significance of PHFs in breast cancer. Thus,
we performed a comprehensive, integrated genomic
and transcriptomic analysis of 98 PHF genes in breast
cancer and identified associations among recurrent copy
number alteration, gene expression, clinicopathological
features, and survival of patients. This approach enabled
us to identify a subset of PHF genes that were recurrently
altered with high prevalence, such as PYGO2 (pygopus
family PHD finger 2), ZMYND8 (zinc finger and MYND
[myeloid, Nervy, and DEAF-1] domain containing
8), ASXL1, and CHD3 (chromodomain helicase DNA
binding protein 3). High expression of ZMYND8 was
significantly correlated with patient survival and was
likely involved in a positive feedback circuit of the ER
pathway in breast cancer. Furthermore, we found that JQ1, a bromodomain and extra terminal (BET) inhibitor,
suppressed ZMYND8 expression in breast cancer. These
findings prioritize a subset of PHFs for future research
focused on understanding molecular mechanisms and
therapeutic potentials in breast cancer.

RESULTS
Copy number and expression profiling of PHFs
in breast cancer
Genetic alterations, including copy number alteration
(CNA) and somatic mutation, are a universal hallmark of
cancer [23, 24]. We hypothesized that PHFs with recurrent
genetic alterations might play important roles in different
types of breast cancer and hence serve as novel therapeutic
targets. Based on the current ChromoHub database, there
are 99 PHFs in the human genome (Supplementary
Figure S1 and Table S1) [25]. We first analyzed CNAs
and mutations in 98 PHF genes (excluding KDM5D on
chromosome Yq11) compiled from 960 breast cancer
specimens in The Cancer Genome Atlas (TCGA) via
cBioPortal [26, 27]. The copy number for each PHF was
generated by the copy number analysis algorithm GISTIC
(Genomic Identification of Significant Targets in Cancer)
and categorized, as copy number level per gene, into
the following: high-level amplification, low-level gain,
diploid, heterozygous deletion, and homozygous deletion
[26, 27]. We first grouped the copy number of each PHF
gene of TCGA breast cancer samples into amp/gain
2
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HER2+, or basal-like subtypes, while KMT2A, TCF20,
PHF21B, EP300, and BRD1 had more deletions in the
Luminal B subtype (Figure 1B, Supplementary Table
S4). A detailed analysis of expression levels of each
PHF in the five breast cancer subtypes also revealed that
expression levels of PYGO2 and KDM5B were higher
in Luminal, HER2+, and basal-like, compared with
their expression levels in the normal-like subtype of
breast cancer (Figure 1, Supplementary Figure S3, and
Supplementary Table S5). We also found that ZMYND8
has a higher expression level in Luminal and HER2+, but
not in the basal-like subtype, compared with that in the
normal-like subtype breast cancer (Figure 1). In contrast,
the commonly deleted genes CHD3 and KMT2A showed
underexpression in HER2+ and basal-like subtypes
(Figure 1, Supplementary Table S5).
To validate our findings from TCGA breast cancer
dataset regarding PHF genetic alterations, we conducted
an independent analysis using the METABRIC dataset,
which contains approximately 2000 primary breast
cancers with long-term clinical follow-up data. We
found that 17 PHF genes, including PYGO2, KDM5B,
PHF20L1, and ZMYND8, had a higher frequency (>10%)
of gain/amplification, and 9 PHF genes, including CHD3
and PHF23, had a higher frequency of deletion in the
METABRIC breast cancer samples (Supplementary
Table S6), although the frequency of gain/amplification
identified in the METABRIC dataset is lower than that
of TCGA dataset, possibly due to the different CNA
analysis platforms and calling algorithms. Furthermore,
statistical analyses of copy number alterations in
METABRIC dataset define 32 regions of amplification and
13 regions of deletion [28]. We analyzed these 45 genomic
regions and found that 11 PHF genes are localized in
significantly amplified regions, including KDM5A in
1q32, WHSC1L1 and ASH2L in 8p11-12, PHF20L1 in
8q13-24, and ZMYND8 in 20q13 (Supplementary Table
S7). We also found that Luminal B breast cancer had
the highest frequency of ZMYND8 gain/amplification in
the METABRIC dataset (Supplementary Figure S4A).
Expression levels of PYGO2, KDM5B, PHF20L1,
and ZMYND8 were also significantly higher in tumor
samples compared to that in non-tumor breast tissue
(Supplementary Table S8). Again, mRNA expression
levels of PYGO2 and KDM5B were higher in Luminal,
HER2+, and basal-like breast cancers, and ZMYND8 was
higher in Luminal B and HER2+ subtypes compared with
that in the normal-like subtype in the METABRIC dataset
(Supplementary Figure S4B; p < 0.001).

(high-level amplification and low-level gain), diploid,
and deletion (heterozygous or homozygous deletions).
As shown in Table 1 and Supplementary Table S2, the 11
most frequently (>40%) amplified/gained PHF genes were
KDM5B, ASH1L, PYGO2, PHF20L1, CREBBP, FBXL19,
DIDO1, ZMYND8, PHF20, ASXL1, and BPTF; and the
9 most frequently (>40%) deleted genes were PHF23,
CHD3, RAI1, KMT2A, TCF20, PHF21B, PHF11, EP300,
and BRD1. The most frequently (>1.5%) mutated PHF
genes were KMT2C, KMT2D, CHD4, ASH1L, ASXL3,
ASXL2, KMT2A, and BAZ2B. Notably, ASH1L exhibited
a higher frequency of both amp/gain (73.93%) and
mutation (1.77%), whereas CHD3 and KMT2A showed
higher frequency of both genetic deletion (61% and
49.01%, respectively) and mutation (1.46% and 1.67%,
respectively) in breast cancer (Table 1 and Supplementary
Figure S2).
We next examined the mRNA expression levels
of each PHF in TCGA breast cancer samples. As shown
in Table 1 and Supplementary Table S2, we found that
three PHFs (PYGO2, KDM5B, and PHF20L1) were
overexpressed at the mRNA level (Z-score > 1) in more
than 40% of breast cancers. PYGO2 had the highest
frequency (51.41%) of mRNA overexpression. In contrast,
the most deleted gene, PHF23, had the highest frequency
(43.48%) of mRNA underexpression (Z-score < -1), and
CHD3 was underexpressed in 35.14% of TCGA breast
cancer samples. We also analyzed the correlation between
copy number and mRNA level of 97 PHFs (excluding
those of KDM5D and KMT2B, as their RNA-sequencing
data were not available) from TCGA breast cancer
specimens. As shown in Supplementary Table S3, almost
all PHF genes had positive correlations between DNA
copy number and mRNA expression, and 24 of them had
a Spearman correlation coefficient (r) > 0.5.
To determine whether the genetic alteration or
mRNA expression of each PHF is specific to a breast
cancer subtype, we analyzed CNA and mRNA expression
independently across different subtypes of 808 breast
cancer samples for which PAM50 (Prediction Analysis
for Microarray 50) subtype data were available [26]. The
frequencies of high-level amplification, low-level gain,
diploid, heterozygous deletions, homozygous deletions,
and somatic mutation of PHF genes in five breast
cancer subtypes are shown in Supplementary Table S4.
mRNA expression status of the PHF genes is shown in
Supplementary Table S5. Among the 11 most amplified/
gained PHF genes, 7 (PYGO2, KDM5B, PHF20L1,
ASH1L, PHF20, DIDO1, and ASXL1) likely had a higher
frequency of gain/amplification in both Luminal and basal
subtypes of breast cancer, and 4 of them (ZMYND8, BPTF,
CREBBP, and FBXL19) were more commonly amplified/
gained in Luminal, particularly Luminal B breast cancer,
than in the normal-like subtype (Figure 1A, Supplementary
Table S4). Among the 9 most deleted PHF genes, PHF23,
CHD3, RAI1, and PHF11 had more deletions in Luminal,
www.impactjournals.com/oncotarget

Recurrent mutations of CHD3-5 and ASXL1-3
genes in breast cancer
Among mutated PHF genes in TCGA breast cancer
samples, we found that 33 PHF genes contained mutations
in the PHD domains (Supplementary Table S9). We
3

Oncotarget

Table 1: Frequency (%) of genetic and transcriptional alterations of PHFs that are highly prevalent in TCGA breast
cancers
DNA Alterations
Gene

Location

mRNA Expression Levels

Amp/Gain

Diploid

Deletion

Mutation

Z
1>Z
Z
Score >= 1 Score > -1 Score <= -1

PYGO2

1q21.3

73.62

25.03

1.36

0.10

51.41

41.92

6.67

KDM5B

1q32.1

75.81

22.63

1.56

1.25

46.09

48.80

5.11

PHF20L1

8q24.22

59.65

35.56

4.80

0.73

41.40

52.03

6.57

1q22

73.93

24.50

1.56

1.77

37.96

51.51

10.53

CREBBP

16p13.3

53.49

38.16

8.34

1.46

32.64

55.16

12.20

BPTF

17q24.2

41.50

46.40

12.10

1.36

32.01

53.81

14.18

DIDO1

20q13.33

48.38

47.13

4.48

0.94

31.60

55.16

13.24

PHF20

20q11.22-q11.23

44.11

50.89

5.01

0.31

27.53

59.12

13.35

ZMYND8

20q13.12

46.72

48.80

4.48

0.52

19.60

69.45

10.95

FBXL19

16p11.2

52.03

39.62

8.34

0.21

19.29

70.91

9.80

ASXL1

20q11.21

42.44

52.87

4.69

0.52

27.53

58.29

14.18

ASXL2

2p23.3

14.91

67.15

17.94

1.67

17.62

64.03

18.35

ASXL3

18q12.1

15.33

55.89

28.78

1.67

2.19

97.81

0.00

CHD3

17p13.1

5.53

33.47

61.00

1.46

6.26

58.60

35.14

CHD4

12p13.31

25.23

60.38

14.39

2.09

19.29

64.65

16.06

CHD5

1p36.31

7.30

53.28

39.42

1.46

1.67

98.33

0.00

KMT2A

11q23.3

9.38

41.61

49.01

1.67

10.74

63.82

25.44

KMT2C

7q36.1

24.71

55.47

19.81

6.99

15.95

68.72

15.33

KMT2D

12q13.12

20.13

65.69

14.18

2.40

17.62

64.23

18.14

BAZ2B

2q24.2

8.45

69.86

21.69

1.56

12.41

69.03

18.56

BRD1

22q13.33

12.20

42.54

45.26

0.63

11.05

55.89

33.06

EP300

22q13.2

10.32

44.00

45.67

1.15

12.20

64.13

23.67

PHF11

13q14.2

7.61

46.30

46.09

0.31

9.38

61.21

29.41

PHF21B

22q13.31

11.37

42.34

46.30

0.31

3.86

96.14

0.00

TCF20

22q13.3;
22q13.2

10.84

42.75

46.40

1.46

12.10

62.46

25.44

RAI1

17p11.2

7.92

37.02

55.06

0.42

9.28

59.54

31.18

PHF23

17p13.1

5.11

33.37

61.52

0.21

6.67

49.84

43.48

ASH1L

noticed that three PHF subfamilies (KMT2A/C/D, ASXL13, and CHD3-5) had higher frequencies of mutation. We
also analyzed frequencies of mutation number per gene
size, and found that the higher frequent mutation ratios
were associated with KMT2C, CHD4, ASXL2, and BAZ2B,
which have mutations of more than 2 per kilobase (kb)
(Supplementary Table S9). We previously reported a
mutation spectrum for KMT2C and KMT2D and proposed
their function as tumor suppressors in breast cancer [29].
www.impactjournals.com/oncotarget

Here, we focused on analyzing the mutation spectrum of
ASXL1-3 and CHD3-5 genes in breast cancer.
The ASXL family consists of three members
(ASXL1, ASXL2 and ASXL3) that share a common domain
architecture: HARE-HTH, ASXH, and a C-terminal PHD.
As shown in Figure 2A and Supplementary Table S10, we
identified a total of 40 ASXL family mutations, consisting
of 7 mutations of ASXL1, 17 mutations of ASXL2, and 16
mutations of ASXL3. One tumor sample (TCGA-BH-A0B9)
4
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Figure 1: Frequencies of PYGO2 and ZMYND8 copy number increase A., and CHD3 and KMT2A deletion B. across five subtypes

of TCGA breast cancer samples. C. Expression levels of PYGO2, ZMYND8, CHD3, and KMT2A across five subtypes of TCGA breast
cancer samples. The differences in PYGO2, ZMYND8, CHD3, and KMT2A mRNA levels among breast cancer subtypes are statistically
significant (p < 0.05).
www.impactjournals.com/oncotarget
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Figure 2: Mutational spectra of ASXL1-3 and CHD3-5 genes in breast cancer. The images show protein domains and the

positions of somatic mutations in ASXL1-3 A. and CHD3-5 B. in TCGA breast cancers. A red dot indicates a nonsense mutation, frameshift
deletion, insertion, or splice; a green dot indicates a missense mutation; and a black dot indicates an inframe insertion or deletion. The data
were obtained from TCGA database via cBioPortal.
www.impactjournals.com/oncotarget
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had three missense mutations (D893H, E1006K, and
G1198V) in the ASXL1 gene, and one sample (TCGAAN-A046) had two nonsense mutations (R357* and R312*)
in the ASXL2 gene. Most of the mutations in the ASXL genes
are localized to the amino-terminal end of the PHD domain.
Previous studies demonstrated that truncation mutations
of ASXLs occur in autism, Bohring–Opitz and related
syndromes, hematological malignancies, and several solid
tumors [21, 22, 30]. Therefore, we predict that mutations at
the amino terminus of the PHD might result in the gain or
loss of function of ASXL proteins in breast cancer.
CHD3, CHD4, and CHD5 belong to the second
subfamily of CHD proteins, which are characterized by
an SNF2-like domain located in the central region as well
as tandem PHD and chromodomains at their C-termini
[31, 32]. The SNF2-like domain is responsible for ATPdependent chromatin remodeling. As shown in Figure 2B
and Supplementary Table S11, we identified a total of 51
CHD3-5 family mutations, consisting of 14 mutations
of CHD3, 22 mutations of CHD4, and 15 mutations of
CHD5, most of which were missense mutations. In the
CHD4 gene, tumor sample TCGA-C8-A27B had two
missense mutations (P90Q and A235P), and TCGAD8-A1JN had one missense mutation (I989F) and an
X34 splice. In the CHD5 gene, one sample (TCGA-D8A1JK) had a missense mutation (H1820Y) and frameshift
deletion (G976Afs*11). Furthermore, we found that one
sample (TCGA-BH-A1FC) had a mutation (D407H) in the
region of the first PHD-finger of CHD3 (Figure 2B).

expression level of each PHF. Supplementary Table S14
summarizes the results of a log-rank statistical analysis of
97 PHFs in breast cancer. High mRNA levels of ZMYND8,
BPTF, PHF20, WHSC1L1, and PHF20L1 were positively
associated with shorter survival in breast cancer patients
(p < 0.05) (Figure 3B, Supplementary Table S14). We
also performed survival analyses of each PHF gene in
Luminal (A and B) subtypes only. In the Luminal subtype,
we found that high mRNA levels of six PHF genes,
PHF20, PYGO1, KDM5A, PHF6, BPTF, and CHD5, were
significantly associated (p < 0.05) with shorter survival in
breast cancer patients. Conversely, low mRNA levels of
KDM4B and ING were significantly associated (p < 0.05)
with shorter survival (Supplementary Table S15). We then
performed a multivariate analysis to investigate whether
the expression level of each PHF was predictive of poor
prognosis compared with standard prognostic markers,
including age at diagnosis, ER status, progesterone
receptor status, HER2 status, tumor size, lymph node
status, metastasis status, and molecular subtype (basal vs.
non-basal). In addition to PHF20L1, which we previously
reported, we also found that high mRNA level of ZMYND8
(p = 0.034, hazard ratio [HR] = 1.92) was independently
associated with shorter survival of TCGA breast cancer
patients (Figure 3C) [33]. Validating this analysis using
the METABRIC dataset, we found that ZMYND8 was
similarly highly expressed in breast cancer samples of
advanced stage and higher grade (Supplementary Figure
S5). We confirmed that higher expression of ZMYND8 was
correlated with a poor prognosis (p = 0.034, HR = 1.16) in
METABRIC breast cancer samples.

Association of PHF gene expression with clinical
features and survival of breast cancer patients

ZMYND8 in the feedback circuit of the ER
pathway was suppressed by the BET inhibitor

To investigate the clinical relevance of PHF
alterations in breast cancer, we examined expression
levels of each PHF gene at different stages of TCGA
breast cancer samples. The means of Z-score and p-value
for each PHF gene across four American Joint Committee
on Cancer (AJCC) stages of breast cancer are shown in
Supplementary Table S12. Among 11 most commonly
amplified/overexpressed PHF genes, we found that three
genes, ZMYND8, PHF20, and DIDO1, were significantly
highly expressed in advanced-stage breast cancers
(T-test: Stage I+II vs III+IV; p < 0.05; Figure 3A and
Supplementary Table S12). Because several PHFs were
more commonly amplified/gained in the Luminal subtype
of breast cancer, we then examined the expression levels
of each PHF gene in different stages of only Luminal
breast cancer samples. We found that ZMYND8 and
PHF20, but not DIDO1, also had significantly higher
expression in advanced stages of Luminal breast cancers
(p < 0.05; Supplementary Table S13).
Next, to analyze the relationship between PHF
mRNA expression and overall survival of breast cancer
patients, samples were divided into high (Z-score >
0) and low (Z-score =< 0) groups based on the mRNA
www.impactjournals.com/oncotarget

In our analysis of the genetic alterations of PHFs
in breast cancer, we found that ZMYND8 had a higher
frequency of amplification and overexpression in
Luminal B breast cancer, and its overexpression was
associated with shorter survival in patients in both
TCGA and METABRIC datasets. We further examined
ZMYND8 expression in a panel of breast cancer cells.
Quantitative reverse transcription PCR (qRT-PCR) and
RNA sequencing showed that ZMYND8 was expressed
more in ER-positive Luminal than ER-negative basal
cell lines (Figure 4A and Supplementary Figure S6).
Because a previous study demonstrated that ZMYND8
physically binds ERα in breast cancer [34], and because
we found that mRNA levels of ZMYND8 were positively
correlated with expression levels of the ESR1 (estrogen
receptor 1) gene (Spearman correlation coefficient (r) of
0.34 in TCGA breast cancer samples), we tested whether
ZMYND8 is a downstream target of the ER pathway.
We treated two ER-positive Luminal breast cancer cell
lines, T47D and ZR75-1, with tamoxifen, the most widely
used nonsteroidal selective ER modulator for adjuvant
7
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Figure 3: A. Expression levels of ZMYND8 across different AJCC stages of TCGA breast cancer samples. B. Kaplan-Meier plots of
overall survival associated with mRNA expression levels of ZMYND8 in TCGA breast cancers. C. Multivariate analysis revealed that
ZMYND8 expression was independent of prognostic variables influencing overall survival of TCGA breast cancer patients.

www.impactjournals.com/oncotarget
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Figure 4: A. mRNA expression levels of ZMYND8, measured by qRT-PCR, in a panel of 21 breast cancer cell lines. mRNA expression

levels in the immortalized but nontumorigenic breast epithelial cell line MCF10A cells were arbitrarily set as 1. Cell lines: green indicates
MCF10A; blue, Luminal breast cancer cell lines; pink, HER2+ breast cancer cell lines; and red, basal-like breast cancer cell lines. B. qRTPCR and C. immunoblot analysis of ZMYND8 expression after treatment with tamoxifen (TAM) in T47D and ZR75-1 cells (*p < 0.05 and
**p < 0.01, Student’s t-test). Protein levels of ERα were also measured by western blot after TAM treatment.
www.impactjournals.com/oncotarget
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therapy of ER-positive breast cancer. Supplementary
Figure S7 shows that expressions of ERα target genes
TFF1 (trefoil factor 1) and MYB were suppressed in T47D
cells after tamoxifen treatment. We found that expression
of ZMYND8 at mRNA and protein levels was also
significantly reduced in those two cell lines after tamoxifen
treatment (Figure 4B and 4C). Next, we analyzed
published data of ERα chromatin immunoprecipitation
sequencing (ChIP-Seq) in ER-positive breast cancer cell
lines [35, 36]. We found that ERα directly bound to the
genomic regions of the ZMYND8 gene. Supplementary
Figure S8 illustrates ChIP-Seq binding sites of ERα at the
ZMYND8 genomic loci in T47D cells [36, 37]. Thus, these
data suggest that a positive regulatory loop between ERα
and ZMYND8 exists in ER-positive luminal breast cancer.
Recent studies demonstrated that bromodomaincontaining protein-4 (BRD4) plays an important role in
promoting estrogen-regulated transcription of ER-positive
breast cancer cells [38]. BRD4 is a member of the BET
family, which also includes BRD2, BRD3, and BRDT.
BRD4 is a major target of BET inhibitors, such as JQ1, which also suppress breast cancer growth inhibition in
vitro and in vivo [39]. We validated that JQ-1 inhibited
growth and survival of both ER-positive luminal T47D
and basal-like SUM159 breast cancer cells (Figure 5A
and 5B). The Western blot assays demonstrated that
JQ-1 downregulated c-MYC, a known target of BRD4,
but there was no measurable effect on ERα expression in
T47D cells (Figure 5C and Supplementary Figure S9). We
also found that JQ-1 dramatically suppressed the mRNA
and protein expression of ZMYND8 in both ER-positive
T47D and ER-negative SUM159 cells (Figure 5C and
5D). Thus, ZMYND8 expression is likely regulated by
multiple mechanisms, including gene amplification, ERα,
and possibly BRD4 pathways in breast cancer.

The PHD finger, which is approximately 5080 amino acids long, is a sequence-specific histone
recognition protein domain [5]. The PHD finger consists
of two anti-parallel β-sheets and a C-terminal α-helix,
which is stabilized by two zinc atoms. Biochemically,
PHD fingers are classified into canonical PHD fingers
that bind to trimethylated histone H3 lysine 4 (H3K4me3)
or noncanonical PHD fingers that bind to differently
modified histones or DNA. H3K4me3 is a histone mark
associated with active transcription. PHD binding of
H3K4me3 occurs through an aromatic cage, similar to
those observed in chromodomain, PWWP (Pro-Trp-TrpPro), and Tudor domains [4, 5]. Of note, one tryptophan
(Trp) residue in the second β-strand of canonical PHD is
absolutely conserved; this Trp forms one of the walls of
the aromatic cage for H3K4me3 binding [5]. In contrast,
noncanonical PHD fingers that bind unmodified histone
H3 lack the second β-strand Trp. Among 99 PHF proteins
with PHD fingers based on the current ChromoHub
database, 57 proteins, including PYGO2, contain only one
PHD, and most of them bind H3K4me3 (Supplementary
Table S1). Thirty-two PHF proteins, e.g. CHD3-5, have
two PHDs, and many of them, particularly those with two
PHDs in tandem, bind unmodified histone H3, due to the
lack of conserved Trp residues in both PHDs. In addition,
11 PHF proteins have more than two PHDs; one of them is
histone methyltransferase KMT2C, which has eight PHDs,
and likely has diverse histone-binding and biological
roles [40]. Furthermore, many PHFs also have additional
epigenetic effector domains, including bromo-, chromo-,
Tudor, and PWWP domains. We found the coexistence of
a PHD and bromodomains in 22 PHF proteins, including
BPTF and ZMYND8; thus, that pairing is considerably
more frequent than the pairing of any other epigenetic
effector domains. Bromodomain is a “reader” of lysine
acetylation [39]. A combined readout of epigenetic marks
by the PHD and bromodomain has been characterized
in several PHFs [4, 41]. For example, the PHD finger
domain of BPTF recognizes methylation signatures at
H3K4me2/3, and the bromodomain selectively binds
to the H4K16ac acetylation mark [41]. Thus, structurefunction studies have highlighted the fact that PHD fingers
recognize histone tails with relatively high specificity
and affinity, making them critical components of various
epigenetic mechanisms.
In this study, we identified four PHFs, PYGO2,
KDM5B, PHF20L1, and ASH1L, which were most
commonly amplified/overexpressed in breast cancer
(Table 1). These data agree with and consolidate prior
reports on the genetic alterations and oncogenic potentials
of these PHFs in various tumors. PYGO2 protein contains
one PHD domain, which regulates β-catenin-mediated
transcription through an interaction with methylated
H3K4 marks [42, 43]. Recent studies demonstrated that
PHD-mediated PYGO2 chromatin binding supports
and enhances mammary gland progenitor proliferation

DISCUSSION
By conducting integrated genomic and transcriptomic
analyses of breast cancers with different molecular
subtypes and clinicopathological features, we identified
a subset of PHF genes, including PGYO2, CHD3, and
ZMYND8, that have high frequencies of CNA and altered
mRNA expression. Different subtypes of breast cancer had
different patterns of copy number and expression of each
PHF. Several PHF genes, e.g. PYGO2, were amplified/
overexpressed likely independent of subtype. Copy number
increase and overexpression of ZMYND8 were more
prevalent in Luminal B subtypes and were significantly
associated with shorter survival of breast cancer patients.
Interestingly, we found that ZMYND8, which physically
binds ERα, is a downstream target of ERα, suggesting
that ZMYND8 is in a positive feedback circuit of the ER
pathway in breast cancer. Furthermore, the expression of
ZMYND8 was repressed after treatment with the BET
inhibitor JQ-1 in breast cancer cells.
www.impactjournals.com/oncotarget
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Figure 5: A. Representative images of cells stained with crystal violet show the effect of JQ-1 on growth and survival of ER-positive T47D
and ER-negative SUM159 cells. B. Bar graphs show relative cells growth after JQ-1 treatment in T47D and SUM159 cells. C. Immunoblot
and D. qRT-PCR analysis of ZMYND8 expression after treatment with JQ-1 in T47D and SUM159 cells (*p<0.05 and **p<0.01, Student’s
t-test). Protein levels of MYC were also measured by western blot after JQ-1 treatment in T47D and SUM159 cells.
www.impactjournals.com/oncotarget
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[44, 45]. Furthermore, loss of epithelial Pygo2 delayed
mammary tumor onset in mouse mammary tumor virus
(MMTV)-Wnt1 transgenic mice [46]. KDM5B was
originally discovered as a gene that was upregulated by
HER2 in breast cancer cells [47]. Consistent with this,
we found that the mRNA expression level of KDM5B
was slightly higher in the HER2+ subtype, compared
with luminal and basal-like subtypes, in both TCGA and
METABRIC breast cancer samples (Supplementary Figure
S3). Inhibiting KDM5B in breast cancer cells has been
shown to reduce proliferation-reduced mammary tumor
growth in vitro and in vivo [48, 49]. In addition, COLT
analysis of the genes essential for cancer cell survival and
proliferation in 29 breast cancer lines identified KDM5B
as a hit in 12 (41%) of these lines (Supplementary Table
S16) [50]. PHF20L1 protein contains two types of histonereading modules, PHD and Tudor domains. PHF20L1 is
amplified and overexpressed in a subset of basal-like and
Luminal B breast cancers. We recently demonstrated that
knockdown of PHF20L1 inhibits cell proliferation in breast
cancer cell lines [33]. We speculate that PHF20L1 likely
functions as a critical tethering factor, via its PHD and
Tudor domains, to regulate DNA and histone methylation
signals in breast cancer [33]. ASH1L, a member of the
trithorax group, is the H3K36 methyltransferase. A recent
study demonstrated that ASH1L is a crucial regulator of
key leukemia target genes and contributes to leukemia
pathogenesis [51]. Thus, these four PHFs are most likely
proto-oncogenes in breast cancer.
In breast cancer, the two most commonly deleted/
underexpressed PHF genes were PHF23 and CHD3.
Fusion of the PHF23 gene with the NUP98 (Nucleoporin
98) gene frequently recurs in acute myeloid leukemia [11].
PHF23 protein contains the canonical PHD finger at the
C-terminus, and the PHD finger is retained in the NUP98PHF23 fusion. The leukemogenic potential of the NUP98PHF23 fusion protein relies on the ability of the PHD finger
to recognize the H3K4me3/2 marks [12]. CHD3, CHD4,
and CHD5 proteins, which share common ATPase domains,
tandem PHD domains, and chromodomains, are catalytic
components of the NuRD (nucleosome remodeling histone
deacetylase) complex [31]. CHD3 and CHD4 are expressed
ubiquitously in every normal tissue, whereas CHD5 is
preferentially expressed in the nervous system and testis.
Both CHD3 and PHF23 genes are localized at 17p13.1, the
TP53 region. A recent study demonstrated that deletions
linked to TP53 loss drive cancer through p53-independent
mechanisms [52]. In that study, a shRNA library targeting
the ~100 protein-coding genes (excluding TP53) in mouse
chromosome 11B3 syntenic to human 17p13.1 was screened
for its tumor-suppressor activity in mouse models. Among
17 identified genes, CHD3 and PHF23 were considered
potential tumor suppressors [52]. In the future, it will be
important to determine how CHD3 and PHF23 play tumorsuppressor roles in a p53-dependent or independent manner
in breast cancer.
www.impactjournals.com/oncotarget

In contrast to CHD3 and CHD5, which most likely
function as tumor suppressors, the role of CHD4 in
various tumors appears to be quite complex. It exhibits
both oncogenic and tumor-suppressing properties [20,
31, 53-55]. Biochemically, the two PHD fingers of CHD4
are able to bind two distinct H3 tails with unmodified
H3K4 and/or H3K9me3, but not H3K4me3 [56]. As the
major component of NuRD, CHD4 has been implicated in
regulating gene transcription and facilitating DNA repair
[55, 56]. Compelling evidence indicates that CHD4 is a
biomarker of drug sensitivity in cancer cells. For example,
using high-throughput genomics, Geeleher et al. revealed
that expression of CHD4 predicted the sensitivity of the
histone deacetylase (HDAC) inhibitor Vorinostat in a
large panel of cancer cell lines [57]. Furthermore, global
proteomic analysis of the NCI-60 cancer cell lines revealed
that the CHD4 protein is the second most recurrent and
significant protein associated with the sensitivity of 97
different drugs [58]. Depletion of CHD4 sensitizes the
CAMA1 breast cancer cell line to Vorinostat or leukemia
cells to genotoxic agents and reduces tumor formation
[53, 57]. In contrast to CHD3, the expression level of
CHD4 was higher in Luminal, HER2+, and basal-like
breast cancer compared with normal-like breast cancers
(Supplementary Figure S10). Thus, CHD4 appears to play
various roles in tumorigenesis and in the development of
drug resistance.
In a recent study of 560 breast cancer samples with
the whole-genome sequences, Nik-Zainal et al. identified
93 protein-coding cancers carrying probable driver
mutations [59]. Five of them (KMT2C, KMT2D, ASXL1,
CREBBP, and PHF6) were PHF genes. Our previous
study, together with others, demonstrated that KMT2C
and KMT2D function as tumor suppressors [29, 60].
The ASXL1 is frequently mutated in a range of myeloid
malignancies [21, 22]. Most cancer-associated ASXL1
mutations give rise to truncated proteins that retain
the amino-terminal BAP1 (BRCA1 associated protein
1)-interacting region of ASXL1, but lose the carboxyterminal PHD domain [21, 22, 61]. Accumulating data
suggest that ASXL1 functions as a haploinsufficient tumor
suppressor in the hematopoietic system [61]. In contrast,
other studies suggested that ASXL1 mutations might
confer a gain-of-function, rather than loss-of-function,
by generating a stable truncated protein lacking the PHD
domain that either serves as a dominant negative function
or generates a new function [61]. In this study, we also
found that ASXL1 gene, localized at 20q11 region, is
commonly amplified/gained in breast cancer (Table 1).
Thus, functional roles of ASXL1 might be altered by gene
amplification or gain-of-function mutations in a set of
breast cancer.
A finding of particular interest from our study is the
dysregulation of ZMYND8 in a subset of breast cancers.
The ZMYND8 protein, which contains an N-terminal
PHD-bromo-PWWP (PBP) cassette and a C-terminal
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MYND (Myeloid-Nervy-DEAF1) domain (Supplementary
Figure S11), has a wide range of interacting partners,
including transcription factors, chromatin remodeling
complexes, and histone demethylase/deacetylase
enzymes. Analysis of the human endogenous coregulatory
complexome revealed that the PBP cassette of ZMYND8
interacts directly with ERα, and both co-occupy a set of
genomic sites of known ERα-binding sites [34]. Results of
gene expression and reporter assay studies confirmed the
coactivator functions of ZMYND8 for ER transcriptional
activity [34]. A recent study revealed that ZMYND8 reads
the dual histone modifications H3K4me1-H3K14ac via
PHD-bromo cassette, and it is associated with repression
of metastasis-linked genes [62]. The MYND domain
of ZMYND8 is responsible for its interactions with the
NuRD complex, notably the core catalytic component
CHD4 [54]. Importantly, ZMYND8 has been identified as
a new DDR (DNA Damage Response) factor; ZMYND8
recruits CHD4 to the sites of DNA damage and represses
transcription and facilitates DNA repair by homologous
recombination [54, 63]. Thus, ZMYND8 is implicated
in both transcriptional activation and silencing, as well as
DNA damage in a context-specific manner. In the present
study, we provided additional evidence that ZMYND8 was
involved in a positive feedback circuit involving the ER
pathway in breast cancer, where the interaction between
ZMYND8 and ERα promotes activation of the ERα target
gene, including ZMYND itself. Furthermore, an additional
regulatory mechanism, such as BRD4’s association with
super-enhancers, might regulate ZMYND expression in
both ER-positive and ER-negative breast cancers. It is
worth noting that, based on the NCBI database, at least
18 transcript variants of ZMYND8 exist. Western blot
also revealed the additional protein bands with molecular
weight lower than full-length ZMYND8 in breast cancer
cell lines, particularly Luminal subtypes (Supplementary
Figure S12). Furthermore, fusion of ZMYND8 has
been identified in lymphoma and breast cancer; both of
the ZMYND8 fusions reportedly remove the MYND
domain but retain the N-terminal PBP cassette [64, 65].
ZMYND8 gene is localized at chromosomal region 20q13,
which also contains candidate breast cancer oncogenes:
MYBL2 (MYB proto-oncogene like 2), ZNF217 (zinc
finger protein 217), and AURKA (aurora kinase A) [66].
As shown in Supplementary Figure S13, we found that
most ZMYND8-amplified breast cancer samples also
showed the amplification of other candidate oncogenes
at the 20q13 region. It is necessary to further investigate
whether and how ZMYND8 contribute, independently or
cooperatively with other 20q13-amplified genes, to breast
tumorigenesis.
In conclusion, our integrated genomic and
transcriptomic analysis identified a broad spectrum of
genetic alterations in PHF genes involved in different
subtypes of breast cancer. Given the higher prevalence of
genomic and transcriptomic alteration of several PHFs,
www.impactjournals.com/oncotarget

such as PYGO2, ZMYND8, ASXL1, and CHD3, it is
necessary to further characterize their structures, roles,
and the molecular mechanisms of the PHD domain that
are implicated in breast cancer initiation and progression.
Furthermore, inhibition of critical epigenetic reader
domains, such as PHD fingers, is emerging as the next
frontier in epigenetic drug development. A few inhibitors
that target PHD fingers, e.g., PYGO2-PHD and the third
PHD of KDM5A, have been reported recently [67, 68].
We anticipate that our findings, along with similar studies
on other types of tumors, will help prioritize which PHFs
to study in order to better understand the molecular
mechanisms and discover novel therapeutic targets in
oncology.

MATERIALS AND METHODS
Cell culture
The cultures for the SUM series of breast cancer
cell lines and the nontransformed human mammary
epithelial cell line MCF10A were described previously
[69]. The Colo824 cell line was obtained from DSMZ
(Braunschweig, Germany), SUM cell lines were obtained
from Dr. Stephen P. Ethier, and all other cell lines in this
study were obtained from ATCC (Manassas, VA, USA).
Cell growth was assessed by using an MTT assay. For
clonogenic survival assays, cells were seeded in 12-well
dishes and treated with JQ-1. After 12 days for SUM159
cells or 20 days for T47D cells, colonies were fixed and
stained with 0.5% crystal violet. Cells were photographed
and counted with an automated mammalian cell colony
counter (Oxford Optronix GELCOUNT, Oxford, United
Kingdom).

The cancer genome atlas (TCGA) data for breast
cancer
The DNA copy number, mutation, and overall
survival datasets of 960 breast cancer samples used in this
research were obtained from the cBio Cancer Genomics
Portal [26, 27]. For each PHF, the copy number was
generated from the copy number analysis algorithm
GISTIC (Genomic Identification of Significant Targets in
Cancer) and categorized as copy number level per gene:
“-2” is a deep loss (possibly a homozygous deletion), “-1”
is a heterozygous deletion, “0” is diploid, “1” indicates
a low-level gain, and “2” is a high-level amplification.
For mRNA expression data, the relative expression of an
individual gene and the distribution of a gene’s expression
in a reference population were analyzed. The reference
population was either all tumors that are diploid for the
gene in question or, when available, normal adjacent
tissue. The returned value indicates the number of
standard deviations away from the mean of expression
in the reference population (Z-score). Somatic mutation
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data were obtained from exome sequencing [26, 27].
Breast cancer subtype and clinicopathologic information
were extracted via the UCSC Cancer Genomics Browser
(genome-cancer.ucsc.edu) and the cBio Cancer Genomics
Portal [6, 26, 27]. Among the 960 breast cancer samples,
808 had subtype data available, including 22 normal-like,
405 Luminal A, 185 Luminal B, 66 HER2+, and 130
basal-like breast cancers [26, 33, 70].

A302-089A, Montgomery, TX, USA), anti-MYC
(1:1000, Cell Signaling D3N8F, Danvers, MA, USA),
anti-ERα (1:1000, Cell Signaling 8644, Danvers, MA),
anti-β-actin (1:5000, Sigma-Aldrich A5441, St. Louis,
MO), and anti-β-tubulin (1:5000, Sigma-Aldrich T8328,
St. Louis, MO, USA).

The METABRIC (molecular taxonomy of breast
cancer international consortium) dataset

Statistical analyses were performed using R
software (http://www.r-project.org) and Graphpad Prism
(version 6.03). Correlations between copy numbers and
mRNA levels of each PHF from TCGA breast cancer
specimens were analyzed using Spearman, Kendall, and
Pearson correlation tests. The Spearman and Kendall tests
are rank correlations—the Spearman coefficient relates the
two variables while conserving the order of data points,
and the Kendall coefficient measures the number of ranks
that match in the data set. We used the “cor” function in
R statistical software for computation, specifying in the
code which type of test we wanted (Spearman, Kendall,
or Pearson). The significance of difference in mRNA
expression level for each PHF among different subtypes
and stages of breast cancer samples was calculated using
ANOVA and Welch’s t-test. To analyze the relationships
between PHF mRNA expression and overall patient
survival in breast cancer, samples were divided into
higher and lower expression groups of each PHF, based
on mRNA expression Z-scores [RNA-Seq V2 RSEM
(RNA-Seq by Expectation-Maximization)] in TCGA
dataset or the log2 normalized expression level in the
METABRIC dataset. Multivariate survival analysis was
conducted in TCGA breast cancer samples using the Cox
regression function (“coxph”) in R. Factors included in
the multivariate analysis model were age at diagnosis
(continuous variable), ER status (positive vs. negative),
progesterone receptor status (positive vs. negative), HER2
status (positive vs. negative), tumor size (>20 mm vs. ≤20
mm), lymph node status (positive vs. negative), metastasis
status (positive vs. negative), and PAM50 subtype (basal
vs. non-basal).

Statistical analysis

The METABRIC dataset contains approximately
2000 primary breast cancers with long-term clinical
follow-up data. METABRIC normal breast expression
dataset (n = 144) was used as a non-cancer, tissue control.
A detailed description of the dataset is presented in the
original publication [28]. The CNAs and normalized
expression data of METABRIC were downloaded with
access permissions from the European Genome-phenome
Archive (https://www.ebi.ac.uk/ega) under accession
number EGAC00000000005. In the METABRIC dataset,
copy number log2 ratios were segmented using two
analytical methods, circular binary segmentation and an
adapted hidden Markov model. The median of the log2
ratio was computed, and gene-centric alterations were
categorized as amplification, gain, heterozygous loss, and
homozygous loss. The data for 98 PHFs were based on
the circular binary segmentation–derived copy number
profiles [28]. The normalized gene expression profiles
were generated using the Illumina Human HT-12 platform
[28].

Semiquantitative PCR reactions
mRNA was prepared from human breast cancer
cell lines and the MCF10A cell line by using an RNeasy
Plus Mini Kit (QIAGEN). mRNA was mixed with qScript
cDNA SuperMix (Quanta Biosciences, Gaithersburg,
MD, USA) then converted into cDNA through a reversetranscription (RT) reaction for real-time PCR reactions.
Primer sets were ordered from Life Technologies
(Carlsbad, CA, USA). A PUM1 primer set was used as a
control. Semiquantitative RT-PCR was performed using
the FastStart Universal SYBR Green Master (Roche
Diagnostics, Indianapolis, IN, USA).
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Immunoblotting and antibodies
Whole-cell lysates were prepared by scraping cells
from dishes into cold RIPA lysis buffer. After centrifugation
at high speed, protein content was estimated by the
Bradford method. A total of 20–50 μg of total cell lysate
was resolved by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred onto a polyvinylidene
difluoride membrane. Antibodies used in the study
included anti-ZMYND8 (1:1000, Bethyl Laboratories
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